Sulfide-Containing Ionizable Lipids for Stable Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems, particularly lipid-DNA conjugates, face challenges such as inflammation when injected locally and accumulation in non-target tissues like lungs and liver, limiting their efficacy and safety for nucleic acid delivery.
Innovation Solution
Development of a sulfide-containing ionizable lipid that forms stable lipid nanoparticles capable of electrostatically encapsulating anionic drugs, specifically targeting the liver or lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lipid-DNA conjugates are used for nucleic acid delivery, then drug delivery efficiency is improved, but inflammation and accumulation in non-target tissues occur
Solution Approach 1:
The patent modifies the chemical structure of ionizable lipids by introducing sulfide-containing groups with specific chain lengths and configurations. This structural parameter change enables the lipid to achieve both high drug encapsulation efficiency and reduced off-target accumulation, resolving the contradiction between delivery efficiency and harmful effects
Solution Approach 2:
The invention creates composite lipid nanoparticles by combining sulfide-containing ionizable lipids with nucleic acids. The unique sulfide group structure enables optimal interaction between the lipid and nucleic acid, achieving high encapsulation efficiency while the specific molecular architecture reduces inflammatory responses and non-specific tissue accumulation
2Quantity of substance
If cationic lipids are used to bind nucleic acids, then encapsulation efficiency is improved, but accumulation in liver and lungs increases
Solution Approach 1:
The patent introduces sulfide groups at specific positions within the lipid molecule (varying chain lengths from C4 to C12) to create local structural features that enhance nucleic acid binding while reducing off-target accumulation. The localized modification of lipid structure allows differential interaction with biological systems
3Ease of operation
If local injection of lipid-DNA conjugates is performed, then targeted delivery is improved, but inflammation at injection site occurs
Solution Approach 1:
The sulfide-containing ionizable lipid structure with specific chain lengths (n=2-7) and sulfide positioning (x=1-3) modifies the physical and chemical properties of the nanoparticle, reducing its immunogenicity and inflammatory potential while maintaining targeted delivery capability through electrostatic interactions with nucleic acids
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid nanoparticles efficiently encapsulate and deliver anionic drugs, such as nucleic acids, with high specificity and stability to the liver or lungs, reducing off-target accumulation and inflammation.
Implementation Method 1
A sulfide-containing ionizable lipid of the disclosure interacts electrostatically with an anionic drug when a lipid nanoparticle is produced, thereby ensuring that the drug is encapsulated in the lipid nanoparticle with high efficiency
Data Source
AI summary
The disclosure relates to a novel sulfide-containing ionizable lipid. The ionizable lipid of the disclosure interacts electrostatically with an anionic drug when a lipid nanoparticle is produced, thereby ensuring that the drug is encapsulated in the lipid nanoparticle with high efficiency and the drug is stably delivered into the body, facilitating its utility in the related art such as lipid nanoparticle-mediated gene therapy.